Mankind Pharma Limited (BOM:543904)

Mankind Pharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	19,129	19,910	19,129	12,819	14,335
Depreciation & Amortization	8,388	5,940	3,697	3,208	1,616
Other Amortization	473.8	272.2	87.3	51.07	49.83
Loss (Gain) From Sale of Assets	23.1	-1,614	-4.8	-16.65	37.41
Asset Writedown & Restructuring Costs	70.4	43.5	131.6	135.6	-22.37
Loss (Gain) From Sale of Investments	-1,262	-1,608	-1,335	-374.31	-1,049
Loss (Gain) on Equity Investments	-116.9	-122.4	-152.1	-124.24	-144.48
Stock-Based Compensation	182.4	266.4	231.9	0.59	-
Provision & Write-off of Bad Debts	200.7	136.1	139.1	137.89	115.43
Other Operating Activities	3,076	2,290	-435.9	609.71	91.25
Change in Accounts Receivable	-1,720	-1,236	-2,899	-2,053	-659.53
Change in Inventory	-507.7	-2,207	-550	2,618	-5,767
Change in Accounts Payable	2,103	-1,460	974.6	-650.19	4,198
Change in Other Net Operating Assets	1,173	3,439	2,299	1,753	-3,633
Operating Cash Flow	31,213	24,134	21,524	18,133	9,198
Operating Cash Flow Growth	29.33%	12.12%	18.70%	97.15%	-19.12%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-6,260	-4,608	-3,153	-7,890	-4,649
Sale of Property, Plant & Equipment	29.9	119.8	75.1	60.48	31.46
Cash Acquisitions	-	-137,027	-	-38.27	-
Divestitures	-	5,625	-	-	-
Sale (Purchase) of Intangibles	-1,113	-593.2	-670	-430.49	-18,807
Sale (Purchase) of Real Estate	-	79.9	-	-	-
Investment in Securities	4,801	9,013	-17,388	-2,366	9,430
Other Investing Activities	576.9	467.7	319.4	123.57	302.84
Investing Cash Flow	-1,964	-126,924	-20,817	-10,541	-13,691

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	39,624	65,622	3,746	10,947	12,723
Long-Term Debt Issued	156.6	58,891	260.9	38.45	58.6
Total Debt Issued	39,780	124,513	4,007	10,986	12,782
Short-Term Debt Repaid	-57,485	-44,799	-3,398	-17,642	-6,454
Long-Term Debt Repaid	-4,934	-6,039	-294.5	-322.25	-104.29
Total Debt Repaid	-62,419	-50,838	-3,693	-17,964	-6,558
Net Debt Issued (Repaid)	-22,638	73,675	314.4	-6,978	6,224
Issuance of Common Stock	214.6	29,632	-	-	-
Common Dividends Paid	-412.7	-	-	-	-
Other Financing Activities	-6,690	-981.3	-261.7	-419.31	-177.86
Financing Cash Flow	-29,527	102,326	52.7	-7,397	6,046

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	156.3	13.1	11.7	23.15	4.78
Miscellaneous Cash Flow Adjustments	-	669.7	-	-	-
Net Cash Flow	-121.9	218.7	771.9	217.6	1,557

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	24,953	19,526	18,371	10,243	4,549
Free Cash Flow Growth	27.80%	6.29%	79.36%	125.16%	-45.31%
Free Cash Flow Margin	17.48%	16.00%	17.90%	11.71%	5.85%
Free Cash Flow Per Share	60.37	48.25	45.79	25.57	11.36
Levered Free Cash Flow	16,748	8,692	11,944	7,117	-16,379
Unlevered Free Cash Flow	20,707	11,323	12,118	7,369	-16,031

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	6,690	981.3	261.7	419.31	177.86
Cash Income Tax Paid	5,927	5,668	4,415	3,231	4,995
Change in Working Capital	1,048	-1,464	-175.7	1,667	-5,861

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 2, 2026

Data Sources Report a data error